Clinical trials: Smouldering Myeloma
Asymptomatic Myeloma
Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma
The purpose of this pilot study is to gain initial insights into the biologic and clinical effects of Atezolizumab in patients with Asymptomatic Multiple Myeloma (AMM).
- Trial name
- NCT02784483
- Testing
- Atezolizumab (1200mg via IV infusion)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Yale University
Smoldering Multiple Myeloma (SMM)
A Prospective Multicenter Study of the Effects of Plant-based Diets on Gut Microbiome and Derived Metabolites in Patients Affected by Smoldering Multiple Myeloma
Our overarching hypothesis is that plant-based diets will induce beneficial modifications of the gut microbiota favoring short fatty acid (SCFA)-producing commensals and a more advantageous CD8/Th17 ratio in sMM patients, thus…
- Trial name
- HiFi-MM (NCT07069751)
- Testing
- diet rich in fiber
- Where
- 5 sites in Italy
- Volunteers
- 62 people
- Sponsor
- Ciceri Fabio
Myeloma
A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma
This is a single-center, single arm, phase I study designed to determine the safety and find the recommended Phase 2 dose (RP2D) or maximum dose level (MTD) of Belantamab Mafodotin in patients with high-risk smoldering multiple…
- Trial name
- NCT05055063
- Testing
- Belantamab mafodotin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Monoclonal Gammopathy of Uncertain Significance, Smoldering Myeloma
Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers
A prospective, pilot study to assess the impact of a 12-month multi-focal lifestyle intervention on myeloma-relevant biomarkers in patients with MGUS or SM.
- Trial name
- NCT06987708
- Testing
- The Multimodal Lifestyle Intervention
- Volunteers
- 67 people
- Sponsor
- Hackensack Meridian Health
AL Amyloidosis, Smoldering Multiple Myeloma
Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
The investigators plan to establish a dedicated network of Italian Hematologic Departments interconnected with the Amyloidosis Research and Treatment Center in Pavia to: 1.
- Conditions
- AL Amyloidosis, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- ProDigALIty (NCT06383143)
- Testing
- no intervention
- Where
- 4 sites in Italy
- Volunteers
- 760 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
The researchers are doing this study to look at how butyrate levels change in participants' stool after they are on a- plant-based diet for at least 12 weeks.
- Trial name
- NCT05640843
- Testing
- Whole Foods Plant-based Diet, Algae Omega 3 + Curcumin
- Where
- 8 sites in United States
- Volunteers
- 180 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Smoldering Myeloma, Smoldering Multiple Myeloma
E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
This research study is aimed to determine the proportion of high risk smoldering multiple myeloma patients who are progression free at 2 years after receiving elotuzumab, lenalidomide and dexamethasone combination therapy.
- Trial name
- NCT02279394
- Testing
- Elotuzumab, Lenalidomide, Dexamethasone
- Where
- 9 sites in United States
- Volunteers
- 51 people
- Sponsor
- Dana-Farber Cancer Institute
Monoclonal Gammopathy of Undetermined Significance, Smoldering Plasma Cell Myeloma
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
The goal of this study is to find markers that may help to predict why some patients who have monoclonal gammopathy of unknown significance (MGUS) or smoldering multiple myeloma (SMM) that have no signs or symptoms of disease…
- Trial name
- NCT02726750
- Testing
- Biospecimen Collection, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Monoclonal Gammopathy, Smoldering Myeloma
Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma
The purpose of this study is to study the safety and preliminary efficacy of a dendritic cell DKK1 vaccine against myeloma. Dendritic cells are immune cells that are collected from the blood of the patient at Case Western Reserve…
- Conditions
- Monoclonal Gammopathy, Smoldering Myeloma, Myeloma
- Trial name
- NCT03591614
- Testing
- DKK1
- Where
- 2 sites in United States
- Sponsor
- Case Comprehensive Cancer Center
Monoclonal Gammopathy of Undetermined Significance, Smoldering Myeloma
Exploring the Effects of Korean-Style Mediterranean Diet (KORMED) and Physical Activity Measurement in Patients With MGUS/SMM: A Pilot Study
This single-arm pilot study aims to evaluate the feasibility and potential health effects of a Korean-style Mediterranean diet (KORMED) and continuous physical activity measurement in patients with monoclonal gammopathy of…
- Trial name
- KORMED-PA Stud (NCT07305662)
- Testing
- KORMED Diet and Physical Activity Monitoring
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Seoul National University Bundang Hospital
Multiple Myeloma, Smoldering Multiple Myeloma
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses [RP2Ds]) and schedule for JNJ-79635322 treatment regimen in combination with daratumumab with or…
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
- Trial name
- NCT06768489
- Testing
- JNJ-79635322, Daratumumab, Pomalidomide
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 276 people
- Sponsor
- Janssen Research & Development, LLC
Smoldering Multiple Myeloma
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
The purpose of this study is to define the natural history of high-risk smoldering myeloma in a modern cohort of patients undergoing close standard of care follow-up with diffusion weighted whole body magnetic resonance imaging.
- Trial name
- SPOTLIGHT (NCT06212323)
- Testing
- Patients with smoldering myeloma undergoing active surveillance with diffusion weighted whole body MRI.
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Utah
Smoldering Multiple Myeloma
A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myeloma.
- Trial name
- NCT02903381
- Testing
- Nivolumab, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma, Smoldering Multiple Myeloma
A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM)
The purpose of this study is to determine the efficacy of treating patients with intermediate risk smoldering multiple myeloma (SMM) with combinational therapy with dexamethasone and lenalidomide (Rd) and patients with high risk…
- Trial name
- iStopMM (NCT03815279)
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- Iceland
- Volunteers
- 80 people
- Sponsor
- Landspitali University Hospital
Plasma Cell Dyscrasias
The Indiana Myeloma Registry
This is a prospective, non-interventional, observational study. The purpose of this study is to collect data and bio-specimens that will support future research
- Trial name
- NCT03616483
- Testing
- This is a non-interventional trial
- Where
- United States
- Volunteers
- 2,500 people
- Sponsor
- Indiana University
Monoclonal Gammopathy of Undetermined Significance, Smoldering Myeloma
Study of DNA Copy Numbers Variations and Gene Expression Profile of Bone Marrow Plasma Cells From MGUS and SMM.
The purpose of this study is to describe DNA copy number variations and gene expression profiles of bone marrow plasma cells of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
- Trial name
- GENOMGUS (NCT01079429)
- Testing
- Genetic study of DNA copies
- Where
- 27 sites in France
- Volunteers
- 1,200 people
- Sponsor
- Rennes University Hospital
Multiple Myeloma, Waldenstrom's Macroglobulinemia
Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders
The purpose of this study is to obtain bone marrow and peripheral blood samples, along with clinical data from patients with Multiple Myeloma (MM), Waldenstrom's Macroglobulinemia (WM), Smoldering MM, and other lymphoplasmacytic…
- Conditions
- Multiple Myeloma, Waldenstrom's Macroglobulinemia, Smoldering Multiple Myeloma, Lymphoblastic Lymphoma
- Trial name
- NCT01177527
- Where
- United States
- Volunteers
- 656 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma, Smoldering Multiple Myeloma
CAR- PRISM (PRecision Intervention Smoldering Myeloma)
The goal of this research study is to test if ciltacabtagene autoleucel (cilta-cel) is safe and effective in treating participants with high-risk, smoldering myeloma.
- Trial name
- NCT05767359
- Testing
- Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Plasma Cell Myeloma, Plasmacytosis
Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase I/II trial studies the safety and best dose of melphalan and bortezomib when given prior to an autologous stem cell transplant and to see how well they work in treating patients with multiple myeloma.
- Conditions
- Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
- Trial name
- NCT02353572
- Testing
- Melphalan, Bortezomib, Dexamethasone
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Colorado, Denver
Multiple Myeloma
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma
Background: Smoldering multiple myeloma (SMM) is a condition that can lead to multiple myeloma, a type of blood cancer. In many high-risk cases, SMM can develop into multiple myeloma in less than 2 years.
- Trial name
- NCT01660997
- Testing
- MLN9708, Dexamethasone
- Sponsor
- National Cancer Institute (NCI)